HPAPI Manufacturing lines  engineered for OEB5

The line is designed for OEB4 and OEB5 processing. The integrated isolator creates a fully closed environment around every critical zone, with automated H2O2 decontamination and validated transfer systems that keep operators separated from the product throughout the entire fill-finish sequence. 

Protection is built into the line architecture rather than added through procedural controls. The isolator encloses filling, closing and vial transfer within a closed barrier. Glove ports and transfer systems are validated for nanogram-level OEL compounds, and automated decontamination removes the need for manual intervention between runs.

The H2O2 decontamination sequence runs automatically within the line control system. Each cycle is triggered, controlled and completed without manual operator steps. A cycle log capturing all key parameters is generated automatically per run, providing traceable documentation for batch records and regulatory review. 

A single-supplier line eliminates the interface gaps that arise when formulation, filling, isolator and freeze-drying equipment come from different vendors. Validation covers the full system under one qualification scope. When a fault occurs, root cause investigation and corrective action involve one accountable partner — not a dispute across multiple vendors. 

Syntegon delivers pre-qualified interfaces between all line components, reducing the qualification effort at each handoff point. A single qualification package covers the full system from formulation through to capped vial, compressing the time between installation and first GMP batch release. 

The filling system typically covers fill volumes from around 0.5 ml up to several hundred ml, accommodating both low-volume, high-value formats common in oncology and targeted therapies, as well as larger-volume HPAPI applications. The exact fill volume range for a given project depends on the selected filling technology, container format, and product characteristics, and is confirmed during line specification. 

The line is designed to help meet applicable requirements under FDA, EMA and EU GMP Annex 1 guidelines for sterile and highly potent drug manufacturing, including aseptic processing standards and containment expectations for OEB4 and OEB5 compounds. Compliance outcomes depend on the specific facility, process and validation programme.

Syntegon supports the full line lifecycle from installation qualification through to ongoing operations. Service offerings include structured commissioning and qualification support, operator training, spare parts supply, preventive maintenance programmes and retrofit or upgrade solutions as production requirements evolve. 

The right filling technology depends on factors such as product viscosity, shear sensitivity, target yield, and containment requirements. Syntegon offers different filling technologies and integrates them into one high-potent line concept, allowing manufacturers to choose the most suitable setup for each application.